Abstract
Antibody-drug conjugates (ADCs) are a series of targeted therapeutic agents for cancer treatment and have succeeded in treating various cancers. Over the years, ADCs have revolutionized cancer treatment by offering new options to patients. These agents act as an alternative to traditional chemotherapy and radiation therapy, and many pharmaceutical companies have developed their own ADC drugs. Based on the available materials, this review discusses the fundamental concepts behind the design of ADC drugs for treating lymphoma. It provides a comprehensive analysis of various marketed ADC drugs from multiple perspectives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
